Opinion

Video

Common Adverse Reactions to EGFR Therapy

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

  1. Provide a broad overview of common adverse effects associated with EGFR-targeted therapies in metastatic NSCLC.
  2. What proactive strategies do you recommend for preventing dermatologic toxicities, such as rash and acneiform eruptions, in patients receiving EGFR-targeted therapies?

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
5 experts in this video
1 expert is featured in this series.
5 experts in this video
5 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
5 experts in this video
Related Content
Image credit: David A Litman | stock.adobe.com
June 11th 2025

Taletrectinib Gains FDA Approval for Locally Advanced or Metastatic ROS1+ NSCLC

Gillian McGovern, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Ambulatory chemotherapy
June 9th 2025

Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC

Luke Halpern, Assistant Editor
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
June 27th 2024

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment

Molecular biologist holding blood sample for EGFR mutation test for the diagnosis of lung disease. Epidermal Growth Factor Receptor.
June 4th 2025

Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC

Luke Halpern, Assistant Editor
Image credit: catalin | stock.adobe.com
Published: June 3rd 2025 | Updated: June 11th 2025

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

Joshua Sabari, MD Kennedy Ferruggia, Assistant Editor